- Home
- FWRG vs AVDL Comparison
FWRG vs AVDL Comparison
Compare FWRG & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FWRG
- AVDL
- Stock Information
- Founded
- FWRG 1983
- AVDL 2015
- Country
- FWRG United States
- AVDL Ireland
- Employees
- FWRG N/A
- AVDL N/A
- Industry
- FWRG Restaurants
- AVDL Biotechnology: Pharmaceutical Preparations
- Sector
- FWRG Consumer Discretionary
- AVDL Health Care
- Exchange
- FWRG Nasdaq
- AVDL Nasdaq
- Market Cap
- FWRG 970.4M
- AVDL 861.4M
- IPO Year
- FWRG 2021
- AVDL 1996
- Fundamental
- Price
- FWRG $17.66
- AVDL $12.75
- Analyst Decision
- FWRG Strong Buy
- AVDL Strong Buy
- Analyst Count
- FWRG 10
- AVDL 7
- Target Price
- FWRG $22.20
- AVDL $19.00
- AVG Volume (30 Days)
- FWRG 1.1M
- AVDL 1.2M
- Earning Date
- FWRG 08-05-2025
- AVDL 08-07-2025
- Dividend Yield
- FWRG N/A
- AVDL N/A
- EPS Growth
- FWRG N/A
- AVDL N/A
- EPS
- FWRG 0.06
- AVDL N/A
- Revenue
- FWRG $1,105,027,000.00
- AVDL $221,075,000.00
- Revenue This Year
- FWRG $21.66
- AVDL $56.78
- Revenue Next Year
- FWRG $16.02
- AVDL $30.46
- P/E Ratio
- FWRG $297.74
- AVDL N/A
- Revenue Growth
- FWRG 14.53
- AVDL 132.35
- 52 Week Low
- FWRG $12.90
- AVDL $6.38
- 52 Week High
- FWRG $22.71
- AVDL $17.30
- Technical
- Relative Strength Index (RSI)
- FWRG 53.06
- AVDL 76.98
- Support Level
- FWRG $16.04
- AVDL $10.79
- Resistance Level
- FWRG $19.50
- AVDL $14.23
- Average True Range (ATR)
- FWRG 1.01
- AVDL 0.59
- MACD
- FWRG 0.03
- AVDL 0.14
- Stochastic Oscillator
- FWRG 46.82
- AVDL 61.15
About FWRG First Watch Restaurant Group Inc.
First Watch Restaurant Group Inc is a daytime restaurant concept serving made-to-order breakfast, brunch, and lunch using fresh ingredients. It generates revenues from Restaurant sales and Franchise revenues.
About AVDL Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.